

RECEIVED

Sheet 1 of 1  
MAY 23 2001

Modified Form PTO-1449

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)  
(Supplemental)

Atty. Docket No.

A-605

Serial No.

TECH CENTER 1800/2900

Applicant

Dunstan

ATTACH 90 #8

Filing Date

September 3, 1999

Group

1642

## U.S. PATENT DOCUMENTS


EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	A3						

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
LA	B1	EP 0 784 093	07/16/97	Europe	/	/	X
	B2						
	B3						
	B4						
	B5						
	B6						
	B7						

EXAMINER'S INITIALS

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

LA	C1	Morony et al, "A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by IL-1 $\alpha$ , TNF- $\alpha$ , PTH, PTHrP, and 1,25(OH) $_2$ D $_3$ ", Journal of Bone & Mineral Research, vol. 14, no. 9, pages 1478-1485, American Society for Bone and Mineral Research (1999)
LA	C2	Perigaud et al, "Nucleoside Analogues as Chemotherapeutic Agents: A Review", Nucleosides and Nucleotides, vol. 11(2-4), pages 903-945, Marcel Dekker, Inc. (1992)
LA	C3	Simonet et al, "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density", Cell, vol. 89, pages 309-319, Cell Press (1997)
LA	C4	Yang et al, "Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy", Cancer Research, vol. 59, pages 1236-1243 (1999)
	C5	
	C6	
	C7	
	C8	
EXAMINER: 		Date Considered: 10/18/01